BeOne registers two trials: first-in-human BON-107 study and myeloma quadruplet with sonrotoclax
BeOne Medicines appears in two newly posted clinical trial registrations covering an early-stage experimental drug and a collaborator-led myeloma combination study.
BeOne Medicines had two new trial registrations posted on 2026-11-12, one as sponsor and one as a listed collaborator.
- BON-107, a phase 1 study (NCT07934069) sponsored by BeOne Medicines, is listed as "not yet recruiting." The trial is the first time BON-107 will be given to humans, and the main goal of the study is to evaluate safety, tolerability, and see how the drug is processed by the body.1 It is set to enroll approximately 100 healthy adult participants, with overall time to participate in this study of approximately two months.1
- SKCD regimen, a phase 2 study (NCT07931391) in early relapsed or refractory multiple myeloma, is listed as "recruiting," with Beijing Chao Yang Hospital as lead sponsor and BeOne Medicines and Wuhan Hiteck Biological Pharma Co., Ltd. as collaborators. The study tests sonrotoclax (BGB-11417), a BCL-2 inhibitor, combined with carfilzomib, a proteasome inhibitor, aponermin (CPT), a TRAIL and DR4/DR5 agonist approved in China for RRMM, and dexamethasone2, with planned enrollment of 66 participants and a primary endpoint of confirmed complete response or stringent complete response during the first nine cycles of SKCD treatment, before initiation of Kd maintenance therapy.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.